Alexion's Soliris granted priority review
14th Nov 2006, 18:19 GMT
Alexion said Tuesday the U.S. Food and Drug Administration granted priority review for Soliris to treat paroxysmal nocturnal hemoglobinuria.
Alexion's Soliris granted priority review related news:
- Alexion's Soliris Granted Priority Review — RedOrbit News - Health
- Alexion Gets Priority Review on Soliris — Bio-Technology News from StratCenter.com
- Alexion Blood Disorder Treatment Granted Priority Review — RedOrbit News - Health
- Alexion gets fast-track FDA review for drug Soliris — bizjournals.com Health Care:Pharmaceuticals headlines
- FDA Grants Priority Review for Soliris BLA for Treatment of Paroxysmal Nocturnal Hemoglobinuria — StratWire - Business of Healthcare NewsFeed
- FDA Grants Priority Review for Soliris(TM) (eculizumab) BLA for Treatment of Paroxysmal Nocturnal Hemoglobinuria — PR Newswire: All Releases
- Mitchell granted the right to appeal his conviction — Scotsman.com News - Jodi Jones murder
- DEP in 99: Accutherm cleanup a priority. — Environmental Health News
- ProactiveNet Granted U.S. Patent for Correlation and Root Cause of Performance Events and Abnormalities — ArriveNet : Technology
- Murder accused granted bail — BBC News | Northern Ireland | UK Edition
Latest news from United Press International - Health Business:
- AmerisourceBergen tests Rx tracking plan
- Lilly: Arxxant cuts sight loss in diabetes
- Merck: Arcoxia heart risk same as Voltaren
- Corcept tests psych. major depression Rx
- Neurogen's obesity drug in phase 1 trial
- Analysis: Insurance horizons expanding
- Dendreon seeks OK for Provenge
- Robots caring for stroke patients
- Diabetes drug stalls heart disease
- Diabetes drug also helps arteries